Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Wall Street Analyst Weigh In
STRO has been the topic of several analyst reports. Wedbush lowered their target price on Sutro Biopharma from $30.00 to $20.00 in a research note on Tuesday, May 10th. JMP Securities restated a "buy" rating and issued a $20.00 target price on shares of Sutro Biopharma in a research note on Wednesday, July 6th. HC Wainwright lowered their target price on shares of Sutro Biopharma from $35.00 to $30.00 in a report on Wednesday, May 11th. Finally, Piper Sandler increased their price target on shares of Sutro Biopharma to $16.00 in a report on Monday, July 4th.
Sutro Biopharma Price Performance
Shares of NASDAQ:STRO traded up $0.43 during midday trading on Monday, hitting $6.19. The company had a trading volume of 427,771 shares, compared to its average volume of 738,003. The firm has a market capitalization of $290.52 million, a price-to-earnings ratio of -2.53 and a beta of 0.94. Sutro Biopharma has a twelve month low of $3.33 and a twelve month high of $23.70. The business has a 50-day simple moving average of $5.09 and a two-hundred day simple moving average of $6.84. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 0.06.
Sutro Biopharma (NASDAQ:STRO - Get Rating) last issued its earnings results on Monday, May 9th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by ($0.05). The company had revenue of $5.90 million during the quarter, compared to analysts' expectations of $11.48 million. Sutro Biopharma had a negative net margin of 215.16% and a negative return on equity of 42.97%. Equities research analysts anticipate that Sutro Biopharma will post -3.27 earnings per share for the current year.